Navidea Biopharmaceuticals (NYSE:NAVB) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a research report sent to investors on Monday. The firm issued a sell rating on the stock.

Navidea Biopharmaceuticals Stock Performance

NYSE:NAVB opened at $0.00 on Monday. The company has a market cap of $100,084.00, a price-to-earnings ratio of -0.02 and a beta of 1.46. Navidea Biopharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $0.13.

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.